Charles Swanton

Charles Swanton is Chief Clinician at Cancer Research UK and a Group Leader at the Francis Crick Institute, where he leads the TRACERx (TRAcking Cancer Evolution through therapy) studies — the most comprehensive cancer evolution studies ever conducted. TRACERx is a prospective multi-regional tumor sampling study tracking lung, breast, and renal cancer evolution from diagnosis through treatment and relapse, using tumor biopsies and serial ctDNA monitoring. This landmark program has revealed how intratumoral heterogeneity (ITH) drives treatment resistance and metastasis. Swanton's discoveries have transformed understanding of how cancers evolve and evade treatment. His work showed that chromosomal instability drives copy number heterogeneity and can predict immunotherapy response, and that tracking ctDNA can reveal the emergence of resistance mutations in real time.

Charles Swanton 是英国癌症研究机构的首席临床医生，也是弗朗西斯·克里克研究所的研究组长，在那里他领导了TRACERx（通过治疗追踪癌症进化）研究——有史以来进行的最全面的癌症进化研究。 TRACERx是一项前瞻性多区域肿瘤采样研究，使用肿瘤活检和序列ctDNA监测从诊断到治疗再到复发追踪肺癌、乳腺癌和肾癌的进化。